Compare AbbVie Inc (ABBV) vs Workiva Inc (WK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Workiva Inc — how do they compare? AbbVie Inc trades at $253.67 (market cap $449.91B), while Workiva Inc trades at $52.55 (market cap $2.97B). The key difference: AbbVie Inc is far larger — about 151.5× Workiva Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| ABBV | WK | |
|---|---|---|
Market Cap | $449.91B | $2.97B |
Sector | Health | Technology |
52-Week High | $261.07 | $93.31 |
52-Week Low | $184.85 | $44.31 |
Enterprise Value | $513.38B | $2.90B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Workiva (WK) trades at $51.54, down 0.75% on the day, with a bullish technical signal from moving averages and strong analyst consensus. The company reported Q1 2026 EPS of $0.77, beating estimates, and shows improving revenue trends. Cash flow from operations grew to $140.07M in 2025, with net income turning positive in 2026 projections. Recent news highlights AI adoption in finance and upcoming Q2 2026 earnings.
Outlook remains positive with a consensus price target of $71.00, implying 38% upside, supported by 16 buy ratings. Risks include high valuation multiples (P/E 214.75) and reliance on sustained earnings growth. The stock presents a growth opportunity if execution continues, but volatility near resistance at $52 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
